Cargando…

Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis

PURPOSE: As one of the classic anti-Canidia albicans (CA) and vulvovaginal candidiasis (VVC) drugs, nystatin (NYS) is limited by poor water solubility and easy aggregation. Traditional NYS vaginal delivery formulations do not fully adapt to the specific environment of the vaginal cavity. The use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ruiteng, Yan, Fang, Cheng, Min, Dong, Fakun, Lin, Yongqi, Wang, Yuzhen, Song, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104221/
https://www.ncbi.nlm.nih.gov/pubmed/32273700
http://dx.doi.org/10.2147/IJN.S241134
_version_ 1783512194472738816
author Song, Ruiteng
Yan, Fang
Cheng, Min
Dong, Fakun
Lin, Yongqi
Wang, Yuzhen
Song, Bo
author_facet Song, Ruiteng
Yan, Fang
Cheng, Min
Dong, Fakun
Lin, Yongqi
Wang, Yuzhen
Song, Bo
author_sort Song, Ruiteng
collection PubMed
description PURPOSE: As one of the classic anti-Canidia albicans (CA) and vulvovaginal candidiasis (VVC) drugs, nystatin (NYS) is limited by poor water solubility and easy aggregation. Traditional NYS vaginal delivery formulations do not fully adapt to the specific environment of the vaginal cavity. The use of exopolysaccharides (EPS) has great application potential in emulsifiers, but its use has not been reported in nanoemulsions. In this work, an EPS/NYS nanoemulsion (ENNE) was developed to improve the activities of NYS against CA and VVC METHODS: The ENNE was prepared by ultrasonic method using EPS as an emulsifier, liquid paraffin oil as an oil phase, PEG400 as a co-emulsifier, and NYS as the loaded drug. ENNE preparation was optimized by response surface method. After optimization, in vitro and in vivo analysis of the anti-CA activity; animal experiments; staining with propidium iodide (PI), periodic acid-schiff (PAS), and hematoxylin-eosin (H&E); and cytokine experiments were performed to investigate the therapeutic ability against VVC. RESULTS: The optimal formulation and preparation parameters of ENNE were determined as follows: EPS content of 1.5%, PEG400 content of 3.2%, NYS content of 700 μg/mL, paraffin oil content of 5.0%, ultrasonic time of 15 min, and ultrasonic amplitude of 35%. The ENNE showed an encapsulated structure with an average particle size of 131.1 ± 4.32 nm. ENNE exhibited high storage and pH stability, as well as slow release. The minimum inhibitory concentration (MIC) of ENNE against CA was only 0.125 μg/mL and the inhibition zone was 19.0 ± 0.5 mm, for greatly improved anti-CA effect. The prepared ENNE destroyed the membrane of CA cells, and exhibited good anti-CA effect in vivo and therapeutic ability against VVC. CONCLUSION: The results of this study will promote the application of EPS in nanotechnology, which should lead to new and effective local drug formulations for treating VVC.
format Online
Article
Text
id pubmed-7104221
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71042212020-04-09 Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis Song, Ruiteng Yan, Fang Cheng, Min Dong, Fakun Lin, Yongqi Wang, Yuzhen Song, Bo Int J Nanomedicine Original Research PURPOSE: As one of the classic anti-Canidia albicans (CA) and vulvovaginal candidiasis (VVC) drugs, nystatin (NYS) is limited by poor water solubility and easy aggregation. Traditional NYS vaginal delivery formulations do not fully adapt to the specific environment of the vaginal cavity. The use of exopolysaccharides (EPS) has great application potential in emulsifiers, but its use has not been reported in nanoemulsions. In this work, an EPS/NYS nanoemulsion (ENNE) was developed to improve the activities of NYS against CA and VVC METHODS: The ENNE was prepared by ultrasonic method using EPS as an emulsifier, liquid paraffin oil as an oil phase, PEG400 as a co-emulsifier, and NYS as the loaded drug. ENNE preparation was optimized by response surface method. After optimization, in vitro and in vivo analysis of the anti-CA activity; animal experiments; staining with propidium iodide (PI), periodic acid-schiff (PAS), and hematoxylin-eosin (H&E); and cytokine experiments were performed to investigate the therapeutic ability against VVC. RESULTS: The optimal formulation and preparation parameters of ENNE were determined as follows: EPS content of 1.5%, PEG400 content of 3.2%, NYS content of 700 μg/mL, paraffin oil content of 5.0%, ultrasonic time of 15 min, and ultrasonic amplitude of 35%. The ENNE showed an encapsulated structure with an average particle size of 131.1 ± 4.32 nm. ENNE exhibited high storage and pH stability, as well as slow release. The minimum inhibitory concentration (MIC) of ENNE against CA was only 0.125 μg/mL and the inhibition zone was 19.0 ± 0.5 mm, for greatly improved anti-CA effect. The prepared ENNE destroyed the membrane of CA cells, and exhibited good anti-CA effect in vivo and therapeutic ability against VVC. CONCLUSION: The results of this study will promote the application of EPS in nanotechnology, which should lead to new and effective local drug formulations for treating VVC. Dove 2020-03-25 /pmc/articles/PMC7104221/ /pubmed/32273700 http://dx.doi.org/10.2147/IJN.S241134 Text en © 2020 Song et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Song, Ruiteng
Yan, Fang
Cheng, Min
Dong, Fakun
Lin, Yongqi
Wang, Yuzhen
Song, Bo
Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis
title Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis
title_full Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis
title_fullStr Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis
title_full_unstemmed Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis
title_short Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis
title_sort ultrasound-assisted preparation of exopolysaccharide/nystatin nanoemulsion for treatment of vulvovaginal candidiasis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104221/
https://www.ncbi.nlm.nih.gov/pubmed/32273700
http://dx.doi.org/10.2147/IJN.S241134
work_keys_str_mv AT songruiteng ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis
AT yanfang ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis
AT chengmin ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis
AT dongfakun ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis
AT linyongqi ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis
AT wangyuzhen ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis
AT songbo ultrasoundassistedpreparationofexopolysaccharidenystatinnanoemulsionfortreatmentofvulvovaginalcandidiasis